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The nucleus accumbens: a target for deep brain
stimulation in resistant major depressive disorder
Cecilia Nauczyciel1†, Suzanne Robic2†, Thibaut Dondaine3, Marc Verin3, Gabriel Robert1,3, Dominique Drapier1,3,
Florian Naudet1,3 and Bruno Millet1,3*
Abstract
Objective: This review aimed to investigate the therapeutic potential of Deep Brain Stimulation (DBS) for treating
resistant Major Depressive Disorder (MDD). We explored the role of Nucleus accumbens (Nac) as a target for
treatment.
Method: We made a systematic review of all studies examining the mechanisms of action of high frequency brain
stimulation and the pathophysiology of MDD. We also reported all the studies exploring the therapeutic potential
of DBS in MDD.
Results: As a central relay-structure, the Nac seems to play a central role in MDD symptomatology. We investigated
its role as a primary target for DBS in depressed patients. Anatomically the Nac is at the centre of the interactions
between dopaminergic, serotoninergic and glutamatergic systems. Functionally, the Nac is involved in both normal
and abnormal reward processes and in anhedonia and loss of motivation. Due to its central location between the
emotional system, the cognitive system and motor control system, the Nac seems to have a central role in mood
and feeling regulation.
Conclusion: According to encouraging recent studies, DBS seems to be a promising technique in resistant MDD
treatment.
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Review
Introduction
Major depressive disorder (MDD) is a common psychi-
atric mood disorder. MDD consists of a single episode or
several instances of recurrent or relapsed episodes of
major depression. According to the DSM IV [1] major de-
pression is characterized by depressed mood or loss of
interest in daily activities. These symptoms can be associ-
ated with physical manifestations such as: significant
weight loss or weight gain, insomnia or hypersomnia, di-
minished ability to think or concentrate and fatigue or loss
of energy. A feeling of worthlessness, excessive or inappro-
priate guilt and recurrent thoughts of death can also been
reported. The symptoms cause clinically significant dis-
tress or impairment in social, occupational, or other im-
portant areas of functioning. MDD is often associated
with a high level of morbidity and mortality and repre-
sents the most important risk factor for suicide on the
whole life (attributable risk of 28% [2]). Although psycho-
pharmacological treatments are effective for many pa-
tients, most of the short-term studies indicate that 29% to
46% of depressed patients remain resistant to treatment
[3]. Given the important negative impact on public health
of MDD, and data suggesting only modest effectiveness of
existing psychological and pharmacological treatments for
chronic Treatment Resistant Depression (TRD), there has
been increasing interest in exploring the therapeutic po-
tential of non-pharmacological interventions, such as
Deep Brain Stimulation (DBS). Recent advances in stereo-
taxic neurosurgical methods have provided an innovative
and promising technique for reducing MDD symptoms in
treatment-resistant patients.
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Place of DBS in brain stimulation treatments of
depression.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a
more recent technique of non-invasive stimulation ap-
proved by FDA for low stages of resistance [4]. Several
studies have compared rTMS with electroconvulsivotherapy
(ECT). ECT showed a higher efficacy in acute severe
depression, psychotic depression and high level of
treatment resistance. It is therefore considered as the
gold standard therapy for patient in TRD with 60% to
90% rate of acute response but with side effects such as
acute cognitive impairment, arrhythmias, and head-
aches. At the long course, this approach is not well
adapted to chronic TRD as DBS might be.
Comparing to TMS and ECT, DBS is an invasive and
still experimental treatment. Even if it is reversible, it re-
quires a complex neurosurgical procedure with a risk of
surgical complications such as infection, intracranial
hemorrhage, lead erosion and migration. Thus, this
treatment should be proposed to patients with a very
high level of resistance. In an ethical point of view, as
well as for scientific reason, this therapeutic procedure
should be recommended under the supervision of an
ethical committee within the frame of an experimental
study [5].
Currently DBS in the subgenual cingulate gyrus, in the
ventral capsule/ventral striatum, and in the nucleus
accumbens (Nac) has showed encouraging results in the
treatment of major depression [6-10].
Based on anatomical and functional arguments as well
as clinical observations we investigated in the present
paper the role of the Nac as a primary target for DBS.
Material and methods
We based our review on electronic and manual litera-
ture search of MEDLINE, PUBMED and PSYCHINFO.
The following terms were included:” Major Depressive
Disorder”, “Deep Brain Stimulation” and “Nucleus ac-
cumbens”. Titles (and abstracts when available) were
screened for relevance, leaving a list of 27 articles
concerning the mechanisms of action of high frequency
brain stimulation and 54 articles concerning the patho-
physiology of MDD and the anatomophysiology of the
Nac. Eventually we reported 5 studies using the Nac as a
target for DBS.
Results
Mechanisms of action of high frequency brain stimulation
An ablation-like effect? Despite its demonstrated clin-
ical efficiency in a variety of neuropsychiatric condi-
tions, the therapeutic mechanisms of DBS remain
unclear. Until the late 1980s, the neurosurgical treat-
ment of choice for disabling drug-resistant tremor has
been ventral intermediate nucleus (Vim) thalamotomy
[11-13]. However, tremor recurred in about 20% of
cases, and the adverse effects were not negligible [12].
DBS use began with Benabid et al’s work [14]. DBS
showed comparable effects to Vim thalamotomy on
tremor. Indeed 88% of the stimulated subjects showed
complete relief from tremor or major improvement of
their symptoms.
These observations led many investigators to con-
clude that DBS acts as a suppressor of neuronal activity
[15,16]. Several mechanisms have been proposed to ex-
plain this inhibition: 1) GABA-mediated suppression
of neuronal activity around the stimulated electrode 2)
elevation of potassium-current, 3) adenosine triphos-
phate (ATP) release and adenosine A1 receptor activa-
tion, and 4) enhancement of the rhythmicity and
synchronous inhibition within and between afferent
structures.
1) STN stimulation in humans could entail a
suppression of neuronal activity around the
stimulated electrode [17,18]. Indeed, chemically
induced thalamic neuronal inhibition by intra
nuclear injection of muscimol (GABAergic agonist)
appears effective in stopping tremor in the same way
as DBS. These results suggest that GABA-mediated
(thalamic) neuronal inhibition may represent a
mechanism underlying the effectiveness of DBS [19].
2) On the other hand, Shin et al. [20] put forward the
hypothesis that stimulation entails an elevation of
potassium-current which decreases neuronal activity
by the activation of an ion conductance resulting in
membrane depolarization. In contradiction to
previously exposed results, any influence of gabazine
(GABAergic antagonist) application was observed,
suggesting a synaptic-independent mechanism. In
the same way in vitro patch-clamp techniques in rat
STN slices [21] have showed that a brief tetanus
produces a full blockade of STN activity, frequency
dependent, which can be repeated without
alteration, and not synaptically induced, since it was
still observed in the presence of blockers of
ionotropic GABA and glutamate receptors or in the
presence of cobalt (voltage-gated calcium-channels
blocker) [21]. Moreover stimulation entailed a
blockage of persistent sodium-current and a
reduction of calcium-mediated responses, suggesting
that T- and L-type calcium-currents are transiently
depressed by stimulation [22].
3) Another explanation could be that DBS causes
adenosine triphosphate (ATP) release in astrocytes,
resulting in accumulation of its metabolite,
adenosine. Afterward adenosine A1 receptor
activation could depress excitatory transmission,
thus causing an inhibitory effect [23].
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4) Eventually a study suggested that high-frequency
Nac DBS suppresses pyramidal cell firing and
enhances slow local field potential oscillations in the
orbitofrontal cortex. This suppression might be
mediated by antidromic activation of corticostriatal
recurrent inhibition. Nac DBS may achieve
therapeutic effects by enhancing rhythmicity and
synchronous inhibition within and between afferent
structures, thereby normalizing function of a neural
circuit that presents aberrant activity in MDD [24].
A conflicting hypothesis: an activation-mediated
effect of DBS However the arguments in favor of a DBS
ablation-like effect are still disputed. Thus, studies in
parkinsonian primates and evidences from microdialysis
studies in human subjects have demonstrated increased
mean discharge rates of neurons in GPi during chronic
stimulation in STN, and GPi stimulation in humans
has been associated with a suppression of neuronal
activity in the thalamus [25,26]. Moreover a Positron
Emission Tomography (PET) study showed that bilat-
eral STN stimulation in patients with Parkinson’s
disease increased blood flow significantly in the left
midbrain while it decreased in cortical regions [26].
Functional magnetic resonance imaging (fMRI) also
showed an increase in blood oxygen level-dependent
signal in the subcortical regions ipsilateral to the stimu-
lated nucleus [27].
Another argument in favour of the activation-hypothesis
is that stimulation in external globus pallidus (GPe) has
been demonstrated to improve bradykinesia [28], and
yet a reduction in GPe output was supposed to worsen
parkinsonian motor signs. Thus the improving effect of
DBS in GPe might occur by a mechanism other than
inactivation of neuronal activity in the stimulated area.
Toward a reunifying explanation These data suggest
that pattern of excitation or inhibition entailed by DBS
is rather complex. Although arguments for increased
output from the stimulated structure seem to conflict
with the hypothesis that stimulation acts to inhibit neur-
onal activity, several hypotheses have been proposed to
explain these paradoxical observations: 1) the activation
of fiber pathways and 2) the independence of firing in
the cell body and axon could resolve the apparently
contradictory experimental results on the effects of DBS.
1) Activation of fiber pathways. Three classes of
neurons can be affected by the stimulation: local
cells, afferent inputs, and fibers of passage [29].
Local cells represent neurons that have their cell
body very close to the electrode; afferent inputs
represent neurons projecting axon terminals to the
region of the electrode and whose axon terminals
make synaptic connections with local cells; and
fibers of passage represent neurons where both the
cell body and axon terminals are far from the
electrode, but for which the axonal process traces a
path closely to the electrode. Currently it remains
unclear which neuron class, or combination of
neuron classes, are responsible for DBS therapeutic
benefit. The effect of stimulation on cellular activity
in the stimulated site could be increased or
decreased, depending on the neurotransmitter of the
afferent fibers. Thus, although high frequency
stimulation may inhibit neurons via activation of
inhibitory afferents, the output from the stimulated
structure may be increased, resulting from the
activation of axonal elements, as they generally
possess a lower threshold for excitation than cell
soma [30].
2) Another possible explanation could be that cell body
firing could not accurately reflect the efferent output
of stimulated neurons. This decoupling of somatic
and axonal activity could explain the paradoxical
experimental results [31].
Eventually the therapeutic mechanisms underlying
high frequency DBS could most likely result from a
combination of several phenomena, and may involve
complex interactions and potential mechanisms of com-
bined grey and white matter stimulation effects [16,32].
Currently, there is a lack of consensus about the mech-
anism of action of DBS and more studies are still neces-
sary to understand its therapeutic potential. Regardless
of whether axons are activated or inhibited by high fre-
quency DBS, defining the specific fiber tracts modulated
by DBS could be a first step toward understanding its
therapeutic mechanisms.
Diffusion-tensor imaging: applications for DBS Diffu-
sion-tensor imaging (DTI) is a non-invasive imaging
technique that can be used to define axonal trajectories
through white matter areas of the brain [33-35]. Johansen-
Berg et al. [36] used probabilistic tractography to define
the likely connectivity of cingulate regions stimulated by
DBS. This technique provides statistical details on how
likely a given pathway is to connect one brain region to
another. Future applications appear for DTI in DBS use:
probabilistic tractography could be used to statistically de-
fine the most pertinent connected anatomical regions
[36]. DTI could also been used to predict the volume of
tissue activated by DBS on a patient-specific basis [37].
Another application of DTI could predict the spatial ex-
tent of action potential generation in response to specific
stimulation parameter settings [38]. Moreover correlation
analyses could be performed with functional imaging data
(fMRI and/or PET) to identify directly stimulated fiber
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populations, and their corresponding cortical and/or sub-
cortical regions. If this kind of analysis was performed on
enough patients it may be possible to statistically define
the “actual target” of DBS. This information would be
highly important in defining an optimal electrode implant-
ation location, and motivate the use of patient-specific
tractography in pre-operative surgical planning.
Pathophysiology of MDD
Functional neuroanatomy of MDD Studies comparing
depressed patients to healthy controls have showed ana-
tomical and metabolic differences between groups in dif-
ferent regions. Frontal cortex has received the most
attention in research on MDD. This focus makes sense,
given the likely involvement of this region in MDD and
its treatment.
Coffey et al. [39] reported a 7% volume reduction of
the frontal lobe among 48 patients suffering from MDD
comparing to 76 healthy volunteer subjects. Similar re-
sults were found in more recent works focused on
orbito-frontal area with a reduction up to 32% compared
with that of normal controls [40-42]. These OFC volu-
metric anomalies were closely associated to a less neur-
onal density [43,44], and to cognitive disturbances [45].
Some vascular modifications [46], as well as a reduc-
tion of the density and size of the neurons were also
highlighted in dorsolateral prefrontal cortex [44]. More-
over voxel- based morphometry (VBM) has been also
used to quantify structural brain changes associated with
MDD. It showed that gray matter was significantly re-
duced in dorsolateral and dorsomedial prefrontal cortex
[47,48].
These observations can be linked to functioning abnor-
malities observed in depressed subject with fMRI. Several
studies have shown an increase of functional activity orbital
and ventro-lateral areas of the prefrontal cortex [49-53].
This hyperactivity was correlated to the severity of depres-
sive symptoms especially with sadness, with thought distor-
tions, pessimism, guiltiness, self-devalorization, and with
anxiety, which accompanies depressive syndrome [54,55].
Increased activity of rostral anterior cingulate and dorsolat-
eral prefrontal lobe has been found during effortful tasks
[56-58]. It suggests a possibly compensatory activity to
maintain task performance. On the other hand, a reduction
of the functional activity of the dorso-lateral and dorso-
median prefrontal cortex was reported in major depression
[49,50,52,59-61]. Moreover, an EEG study showed that
within depressed persons, lower bilateral PFC activity pre-
dicts higher levels of rumination [62].
However, while the prefrontal cortex is undoubtedly
involved in clinical aspects of MDD, it is unlikely that
dysfunctions in this region can explain all the symptoms
of this disorder. Indeed frontal regions are implicated in
working memory, attention, impulse control and other
aspects of executive function. Abnormalities in these
cognitive domains are observed in MDD, but it could be
argued that such symptoms do not represent the main
part of the symptomatology in many patients. Indeed a
striking observation is the extent to which abnormalities
in reward and motivation domains are seen in MDD.
For example, most depressed patients prominently ex-
hibit a reduced ability to experience pleasure (anhedo-
nia) and loss of motivation, as well as abnormalities in
several neurovegetative functions such as appetite, sleep,
energy level, and circadian rhythms 1. The brain’s re-
ward regions could be at the heart of the MDD’s mani-
festations. Studies from the drug addiction field have
identified the nucleus accumbens (Nac; part of the ven-
tral striatum) and its dopaminergic inputs from the ven-
tral tegmental area (VTA) of the midbrain, as the one of
the most important anatomical substrates for drug re-
ward as well as for natural rewards, such as food, sex,
and social interactions [63].
The neurotransmitter traffic and neurogenesis These
forebrain networks are modulated by monoamine pro-
jections from midbrain and brainstem nuclei (dopamine
from the ventral tegmental area (VTA), serotonin from
the dorsal raphe located in the periaqueductal grey area,
and noradrenaline from the locus coeruleus) [64]. All
available antidepressant medications are based on seren-
dipitous discoveries of the clinical efficacy of two classes
of antidepressants more than 50 years ago. These tricyc-
lic and monoamine oxidase inhibitor antidepressants
were subsequently found to promote serotonin or nor-
adrenaline function in the brain. Newer agents are more
specific but have the same core mechanisms of action in
promoting these monoamine neurotransmitters [65].
Glutamate is also involved in the physiopathology of
the MDD: studies showed that systemic administration
of a N-methyl-D-aspartate (NMDA) antagonist have an
antidepressant effect by rodents exposed to a chronic
stress, and weak dose of NMDA antagonist administra-
tion entails an improvement of mood by depressed pa-
tients [66]. Glutamate also plays a modulation role of
DA release. Indeed, administration of NMDA antagonist
in Nac entails an increase of DA release [67]. Moreover
recent works on the NMDA receptor antagonist keta-
mine showed that this substance leads to rapid and rela-
tively sustained antidepressant effects in patients with
treatment-resistant MDD [68,69]. Animal studies sug-
gested that this antidepressant effect could be mediated
by enhancing AMPA relative to NMDA throughput in
critical neuronal circuits [70,71].
Moreover brain-derived neurotrophic factor (BDNF) reg-
ulates many neuronal aspects including cell differentiation,
cell survival, neurotransmission, and synaptic plasticity in
the central nervous system [72]. Its function is mediated by
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its binding to specific receptors, such as the TrkB receptor
and the pan [73] neurotrophin receptor (p75NTR). BDNF
expression is closely regulated by neuronal activity.
Localization of the TrkB receptor also increases at synaptic
sites after neuronal activity. p75NTR is a low-affinity re-
ceptor of BDNF, and it can mediate neuronal apoptosis
only when the Trk receptor is less or not active [74]. Not-
ably, it is possible that alteration in the expression and/or
function of BDNF in the central nervous system is involved
in the pathophysiology of various brain diseases, including
depression [72]. Indeed in mouse model a passive profile
(chronically defeated, with a high level of immobility and
low non-social exploration) was associated with a lower
hippocampal BDNF level than in mice with active profile.
Therefore, it has been proposed that MDD is associated
with impaired neuronal plasticity and that antidepressant
treatments promote several forms of neuronal plasticity,
including neurogenesis, synaptogenesis and neuronal mat-
uration and also increase BDNF activity [74].
Endocrinology On the other hand, glucocorticoids,
stress-induced steroid hormones, also putatively contrib-
ute to the pathophysiology of depression [72]. MDD has
been associated with impaired mineralocorticoid recep-
tor function [73] and raised cortisol level [75]. Interest-
ingly, in addition to the reduction in BDNF levels due to
increased glucocorticoid exposure, current reports dem-
onstrate possible interactions between glucocorticoids
and BDNF-mediated neuronal functions. Other steroid
hormones are involved in numerous neuronal events in-
cluding cell survival and synaptic plasticity. Kendall et al.
[76] have shown the influence of sex hormones (testos-
terone and estrogen) on antidepressant-induced alter-
ations in 5HT-2 receptor binding. Moreover, it has
been proved that estrogen plays a role in the patho-
physiology of Parkinson’s disease, Alzheimer’s disease,
and mental illness, while serving to regulate BDNF ex-
pression and function [72]. Moreover the estrogen
decrease may be a factor in both the pathogenesis of
late-life depression of the postmenopausal state and in
therapeutic response [77].
Nucleus accumbens and MDD: anatomical arguments
Anatomical reminder The Nac belongs to a subcortical
telencephalic and diencephalic set of nuclei: the basal
ganglia. It is located immediately underneath the anter-
ior limb of the internal capsule and covers a large area
of the basal forebrain rostral to the anterior commissure.
Medially adjacent to it is the diagonal band of Broca; lat-
erally adjacent to it are claustrum and piriform cortex.
The Nac is dorsally adjacent to the rostral extensions of
the globus pallidus and the anterior limb of the internal
capsule. Dorso- laterally, the Nac extends into the ven-
tral putamen, dorso-medially into the ventral caudate
(i.e the ventral striatum). The Nac is divided into two
parts: a central core and a peripheral shell. The central
core is associated with the extrapyramidal motor,
whereas the peripheral shell is associated with the limbic
system [78].
Within the Nac, information is transmitted from shell
to core. Nac core receives a dense dopaminergic input
from the ventral tegmental area (VTA) and the dorsal
tier of the substantia nigra, but also serotoninergic and
noradrenergic afferences of respectively the raphe nu-
clei and the locus coeruleus, which are themselves in-
nervating hippocampus, amygdala and VTA. The Nac
receives glutamatergic afferences from the hippocam-
pus, the baso-lateral amygdala and the prefrontal cortex
[79]. Its main efferents innervate the pallidum, stri-
atum, mediodorsal thalamus, prefrontal cortex and
mesolimbic dopaminergic areas.
Thus the Nac occupies a central position between lim-
bic structures (basal ganglia, amygdala, and mediodorsal
nucleus of thalamus) and cognitive structures as pre-
frontal cerebral cortex. This key position allows it to play
an important role in control of locomotion, motivation
and in reward processing. Since dopamine (DA) is a
major transmitter in the Nac, a function of modulation
on amygdaloid–basal ganglia– prefrontal cortex circuitry
can be supposed.
Dopaminergic pathways Dopaminergic mesolimbic and
mesocortical systems are involved in hedonia and motiv-
ation, two important dimensions in clinical picture of
MDD. Several lines of evidence implicate the mesolimbic
DA system in the pathogenesis and treatment of MDD.
The mesolimbic pathway sends projections from VTA to
the limbic system via the Nac, the amygdala, and the
hippocampus as well as to the medial prefrontal cortex.
Dopaminergic neurons label environmental stimuli with
appetitive value, predict rewards and motivating events
and poor adaptation of the DA system may be involved
in MDD [80].
Serotonin-Dopamine-Glutamate interactions in the
nucleus accumbens Social defeat stress in animals leads
to alterations of the mesolimbic DA system, and in an
interesting manner the behavioral changes in these ani-
mals were reset by chronic application of a selective
serotonin reuptake inhibitor (SSRIs) [81]. SSRIs are effi-
cacious in MDD because of their ability to increase sero-
tonin neurotransmission. This increasing might result in
a suppression of the firing activity of DA neurons [81]. It
has been showed that glutamate release in the Nac is in-
volved in depressed behaviour during the Porsolt swim
test [82]. Glutamate interacts with serotonin in the Nac:
indeed NMDA antagonist perfusion in Nac entails an in-
crease of serotonin release [80,83]. Beyond its key role
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from the anatomical point of view, there are functional
evidences of the interest of the Nac as a target for DBS
by depressed patients.
Nucleus accumbens and MDD: functional arguments
Implication of the nucleus accumbens in normal and
abnormal reward processes Depressed subjects show
accentuation of the negative perceptions along with in-
capacity to feel pleasure during positive stimulations.
The ventral striatum, and especially the Nac, is a central
region for processing reward and pleasure information.
Increases in Nac neuron activity and DA release are ob-
served during experience of rewards. The ventral stri-
atum shows abnormal activity following administration
of dextroamphetamine in patients with MDD, compared
with activity observed in healthy control subjects. Dex-
troamphetamine is a DA releaser and a DA reuptake
inhibitor with secondary serotonergic- and noradrenergic-
releasing effects. At safe doses (5–60 mg), dextroamphet-
amine reliably stimulates brain reward system sites and
produces measurable, characteristic, and well-studied
pleasurable effects such as euphoria and increased drive.
These results suggest the presence of a hypersensitive re-
sponse in the brain reward system of depressed patients,
which may reflect a hypofunctional state [84]. Further-
more, a recent study suggests that the reward system basal
ganglia dysfunction in MDD may affect reward processing
[85]. Thus the Nac is a critical centre for the experience of
reward and pleasure, and is dysfunctional in patients suf-
fering from MDD9.
Implication of the nucleus accumbens in anhedonia
and loss of motivation One core symptom of MDD is
anhedonia, characterized by a lack of reward- motivated
behavior, associated with a decreased experience of pleas-
ure or interest in previously enjoyed activities. Anhedonic
symptoms are linked to reward responses in key nodes of
the reward system. The Nac acts as a “motivation gateway”
between limbic systems involved in emotion, and systems
involved in motor control. Loss of motivation and anhedo-
nia found in the MDD can be bound to abnormalities of
the reward system (dopaminergic mesolimbic pathway,
whose VTA and Nac are the main actors).
Indeed a study of Yadid et al. [86] showed that re-
peated stress infers an increase of the DA release in Nac
by normal rats but not by model rats of MDD, while a
neuroimaging study found attenuated Nac activation in
response to positive words in depressed subjects [17,87].
A negative correlation between anhedonic symptoms
and Nac responses to positive stimuli in a monetary
gains paradigm has also been measured. Additionally, a
morphometric study suggests that anhedonia in MDD is
negatively related to the Nac volume [88]. In contrast to
a previous study [89], this association was shown to be
specific to Nac and did not extend to other basal ganglia
regions (i.e.: anterior caudate volume).
Moreover, depleting DA from the shell region of the
Nac in rats severely impairs their ability to engage in
reward-seeking in a drug self-administration paradigm
[90]. The Nac implication in anhedonia phenomenon
may be mediated by the transcription factor cAMP re-
sponse element-binding protein (CREB), since it plays
an important role in regulating mood. In rodents,
increased CREB activity within the Nac produces
MDD- like symptoms, including anhedonia, whereas
disruption of CREB activity by expression of a dominant-
negative CREB (mCREB, which acts as a CREB antagonist)
has antidepressant-like effects. These studies support the
hypothesis that disruption of CREB in the Nac influences
motivation by facilitating reward and reducing depressive-
like states such as anhedonia and dysphoria [91].
Thus, the Nac mediates motivational behavior related
to obtaining rewards. The Nac seems to be a key target
in the treatment of MDD since anhedonia is one of the
key defining symptoms of the disorder [9].
The nucleus accumbens: at the centre of a circuit in-
volved in MDD The Nac is in connexion with VTA, the
amygdala, orbitofrontal cortex, medial prefrontal cortex,
motor regions such as the dorsal caudate and globus
pallidus, and the hippocampus; and it turn indirectly
projects to cortical regions including subgenual cingulate
in Brodmann area 25 (Cg25) and medial prefrontal cor-
tex, the ventral pallidum, the thalamus, and amygdala
[91,92] (see Figure 1). These connections of the Nac can
be GABA-ergic or glutamatergic [47]. Evidence from
neuroimaging, neuropathological, and lesion analysis
studies show that many of these regions are implicated
in identification of the emotional value of a stimulus,
production and regulation of affective states, and auto-
matic regulation of emotional responses [51].
The relationships between the medial prefrontal cor-
tex, the rostral anterior cingulate cortex, and the amyg-
dala appear to reflect an interaction between the self-
referential processing and the negative emotional infor-
mation processing and these interactions might be asso-
ciated with depressive symptoms [93].
Altered functioning in patients with MDD The Nac
proved to be dysfunctional regarding rewarding stimuli
in patients with MDD. In a functional imaging study of
Epstein et al. [87], words with positive, negative or neu-
tral value were proposed to depressed subjects versus
control subjects. The results showed by depressed sub-
jects a cortical activation significantly decreased at the
level of the ventral striatum during presentation of
words with positive value, correlated with the degree of
loss of pleasure. These findings showed a dysfunction of
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the circuit of reward in the MDD underlined by neur-
onal substrates (dopaminergic pathways and Nac).
In another study [94] the authors combined fMRI with
a dopaminergic probe (a dose of oral dextroamphet-
amine sulfate) to stimulate the brain reward system.
Subjects with MDD showed a hypersensitive response to
the rewarding effects of dextroamphetamine, with al-
tered brain activation in striatal regions (including head
of caudate, putamen and nucleus accumbens).
Taken together, these findings support a model of
MDD including reward/motivational pathway dysfunc-
tion and suggest a crucial role of the Nac in the inability
to experience pleasure or engage in rewarding activities.
Encouraging results
Because of its central role in reward circuitry and its dys-
functions regarding rewarding stimuli in patients with
MDD the Nac appears to be a key structure in MDD treat-
ment with DBS. There have been several reports to date
on the effectiveness of stimulating of the Nac in preclinical
studies and in patients suffering from MDD.
Pre clinical studies Pre-clinical studies on animal
models provide a better understanding of the mechanisms
underlying the action of DBS. Hamani et al. [95] reviewed
the findings with DBS on rodents for depression. Contrary
to human studies where DBS is continuous, in preclinical
studies, intermittent patterns have been investigated. In
the study of Hamani et al. [96], DBS of the VMPFC and
the NAC increased sucrose preference in a chronic mild
unpredictable stress model, reflecting antidepressant like
effects [97,98]. Falowski et al. [99] studied DBS of the
NAC in animal model of depression and showed an anti-
anhedonic effect of DBS by an increase of the exploratory
behavior and a decrease of an anxiety-like behavior. Dopa-
mine and norepinephrine levels decrease and the length of
apical and basilar dendrites in pyramidal cells increased
supporting the hypothesis of a neuroplasticity induced by
DBS. Interestingly, two other models of depression (help-
lessness model and tail suspension test) did not improve
after DBS of VMPFC.
Clinical studies The effectiveness of DBS in the ventral
caudate nucleus in improving depressive symptoms was
Nac shell
INSULA
ORBITO-FRONTAL 
CORTEX MEDIAL 
PREFRONTAL 
CORTEX
SUBGENUAL 
CINGULATE
MEDIO-
DORSAL 
THALAMUS
VENTRAL 
PALLIDUM
SUBTHALAMIC 
NUCLEUS
BASOLATERAL 
AMYGDALA
CENTRAL 
AMYGDALA
Neuromodulator projection systems :
VTA (DA)
Substantia nigra compacta (DA)
Raphe nuclei (Serotonin)
Locus coeruleus (NA)
Nac core
(Glut)
Sensory
informations
Projections
Glutamatergic projections
Sensory informations
HIPPOCAMPUS
Figure 1 Schematic of the limbic corticostriatal loop (from a schematic by Cardinal, 2006 showing key structures involved in reward
process and anhedonia and loss of motivation observed in MDD. DA: dopamine, Glut: glutamate, NA: noradrenalin, VTA: ventral tegmental
area. The Nac seems to be at the centre of this circuitry: between the emotional system (amygdala, basal ganglia, insula, medial prefrontal cortex,
orbitofrontal cortex, VTA), the cognitive system (anterior cingulate cortex) and motor control system (hippocampus).
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first reported in a case of primary treatment- resistant
obsessive-compulsive disorder with concomitant MDD6.
The patient underwent bilateral electrode stimulation
with the deepest contact located in the Nac, and the
superficial contact in the ventromedial caudate. DBS of
the ventral caudate nucleus gradually improved depressive
and anxiety symptoms until remission at six months, in
parallel with an improvement in psychosocial functioning.
Nevertheless, the psychiatric comorbidity in this patient
limits extrapolation of these data to patients with clinical
picture of only MDD. Afterwards, Aouizerate et al. (2009)
tested DBS of the ventral striatum in two patients suffer-
ing from severely distressing and intractable forms of
obsessive-compulsive disorder and MDD. Electrodes were
implanted into the ventral striatum (including the head of
the caudate nucleus and the Nac). Authors observed by
the first subject an improvement in HDRS scores at six
months after surgery; this improvement remaining up to
fifteen months after surgery. A depressive symptoms
worsening was first observed by the second subject over
the first three months, afterwards a reduction of HDRS
scores was observed, until remission, nine months after
surgery. In another study, three patients suffering from ex-
tremely resistant forms of MDD were implanted with
bilateral DBS electrodes in the Nac. Clinical ratings im-
proved in all three patients when the stimulator was on,
and worsened in all three patients when the stimulator
was turned off. Effects were observable immediately, and
no side effects occurred in any of the patients. Using
FDG-PET, significant changes in brain metabolism as a
function of the stimulation in fronto–striatal networks
were observed [7]. Bewernick et al. in 2010 [8] studied the
long- term effects of DBS in the Nac in a more important
group of 10 patients. Twelve months following initiation
of DBS treatment, five patients reached 50% reduction of
the HDRS. The number of hedonic activities increased sig-
nificantly by these patients. Interestingly, ratings of anxiety
(Hamilton Anxiety Scale) were reduced in the whole
group, markedly in the responder group. The positron
emission tomography data revealed that Nac-DBS de-
creased metabolism in the subgenual cingulate and in pre-
frontal regions including orbital prefrontal cortex. A
sustained effect of NAc DBS was shown in 5 out of 11 pa-
tients at four years of follow-up [100].
The Nac is not the only target of DBS in human Treat-
ment Resistant Depression (TRD). Five other areas have
been stimulated. Anderson et al. [101] and Blomstedt
et al. [102], reviewed these different targets and their ef-
ficacy. The most studied target is the subgenual
cingulated gyrus (SCG). Mayberg et al. [103] showed an
hyperactivity of this area in TRD patients compared to
healthy subjects and Kennedy et al. [104] have shown
that SCG might be considered as a biological marker of
resistance. Three independent studies including 20
patients were realized with a mean reduction of of 52%
after 1 year, at the HDRS score. Ventral capsule/ventral
striatum (VC/VS) is another target of DBS, also used in
refractory OCD [105]. A multicentre study driven with
17 patients showed a mean reduction at the HDRS score
of 44%, after 1 year [10]. Two other targets have been
proposed with only case reports: inferior thalamic ped-
uncle because of antidepressant effect on preclinical
model and lateral habenula because of hypermetabolism
on depressed patients and on preclinical model. Re-
cently, some promising results have been observed by
targeting the foramen median bundle [106]. Currently,
none of the targets has proved its efficacy in a random-
ized control trial.
Discussion
Our review put forward the central role of the Nac in
the physiopathology of MDD. Indeed anatomically and
functionally the Nac is at the centre of the reward
circuit involved in MDD. This structure is involved
in both normal and abnormal reward processes and
shows an altered functioning in patients with MDD.
Moreover several clinical studies indicate the effective-
ness of DBS in the ventral caudate nucleus in improv-
ing depressive symptoms.
Nevertheless, several limits should be noticed concerning
the use of DBS applied to the Nac.
Parameters of DBS in Nac
In the human studies [8,9] stimulating the NAC in
MDD, parameters of stimulation were adapted at patient
response. Although the pulse-width and frequency of
stimulation remained stable (respectively 130Hz and
90micros), the voltage was adapted from 1,5 V up to
10 V with an increase of the voltage for non responders.
The ideal settings to reach an antidepressant response
are still unclear.
Pre clinical studies in animals were realized in order to
improve the different parameters. In a large animal study
using functional Magnetic Resonance Imagery (fMRI)
during the stimulation of the NAC, the increase of the
voltage from 3 to 5 V lead to an increase of the Blood
Oxygenation Level Dependent (BOLD) signal in insula,
thalamus and parahippocampal cortex and to a decrease
in the cingulate and prefrontal cortex [99]. This study
showed that functional response relies on effective
level of currents. But, in a study on rodents testing the
optimal setting using DBS in prefrontal ventromedial
prefrontal cortex(VMPFC), Hamani et al. [96], showed
that increasing the current up to 130HZ with a charge
density of 100-130uA was associated with a worsening
of the response. It implies that under and above a cer-
tain threshold, DBS could be ineffective.
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At the present time, both shell and core were stimu-
lated in DBS studies. It is difficult to determine which
amelioration is due to the core’s stimulation and which
one to the shell’s one. However it will be important in
the future to determine how DBS acts on each struc-
ture. The role of Nac shell and core is quite well docu-
mented, but their role in MDD is still to determine
more precisely.
Generally, the shell seems to constitute a limbic sector
of the brain involved preferentially in motivational and
emotional processes, whereas the core may comprise a
striatal sector that plays a role predominantly in motor
functions [107]. Pharmacological methods have shown
differences between the Nac core and Nac shell in basal
DA metabolism, and indicate that the core and shell DA
innervations can be distinguished on the basis of re-
sponse to both pharmacological and environmental chal-
lenges. These data were consistent with the hypothesis
that the dopaminergic innervation of the Nac core is as-
sociated with the nigrostriatal system, while that of the
Nac shell is related to the mesolimbic system [108]. Both
microdialysis and voltammetry studies have shown that
several drugs of abuse, such as cocaine, morphine, am-
phetamine and nicotine preferentially increase extracel-
lular dopamine in the shell compared to the core of the
NAC [109]. Excitotoxic lesions have also been used to in-
vestigate the functions of the Nac core and shell in animal
models [110]. These results indicated a functional dissoci-
ation of subregions of the Nac in mediating amphetamine-
potentiated conditioned reinforcement and locomotion.
The shell appeared to be a critical site for stimulant effects
underlying the enhancement of conditioned response and
locomotion after intra-Nac injections of amphetamine,
whereas the core seemed to be implicated in mecha-
nisms underlying the expression of conditioned stimu-
lus and unconditioned stimulus association. An animal
study also showed that DBS of the Nac shell signifi-
cantly attenuated the reinstatement of drug seeking
precipitated by high cocaine doses whereas DBS of the
dorsal striatum had no influence on cocaine reinstate-
ment [111]. Since the shell seems to constitute a limbic
sector of the brain involved preferentially in motiv-
ational and emotional processes, we tend to think that
it will become a preferential target in depression
treatment.
The issue of the long term antidepressant benefit of
Nac DBS seems to be solved as showed in Bewerick et
al’ studies [8,100]. However, potential concerns regarding
possible long-term habituation with stimulation of the
Nac can be questioned. Intracranial self-stimulation has
been largely studied in animals. In this behavioural para-
digm, animals repeatedly press a lever to stimulate their
own dopamine-releasing neurons electrically. Dopamine
and GABA neurotransmission in the Nac play a role in
this phenomenon; with robust changes in cell firing of
many Nac units [112,113]. Moreover a case of habituation
has been reported by a subject with obsessive-compulsive
disorder [114]. This subject exhibited intra-operatively
an asymmetric smile and acute positive emotional
change with DBS in Nac and anterior limb of the in-
ternal capsule region. Chronic DBS resulted in habitu-
ation of the smile response. This habituation was
characterized by the loss in intensity of the facial response
during successive testing over the initial 3 months follow-
ing surgery. At 6 months and a year following the opera-
tive procedure, longer washout periods in the “DBS-off”
condition of 16 hours and 2–4 weeks respectively (on the
right side), failed to restore the smile or affective response.
These findings imply potential habituation and changes in
the neural chemistry (possibly neuroplasticity) induced by
chronic DBS.
Conclusions
To conclude there are strong preclinical and clinical ar-
guments to consider that DBS of the Nac may be an ef-
fective strategy in MDD treatment. Recently DBS to
brain structures mediating reward and motivation pro-
cesses has showed encouraging results. It is also interest-
ing to notice few side effects of this treatment have been
observed. Nonetheless the therapeutic mechanisms of
DBS must be still determined; these findings might offer
a focused and novel approach to treating refractory
MDD with a favorable efficacy to side effect profile.
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